News for Atara Biotherapeutics, Inc. (ATRA)

The consensus price target hints at a 33% upside potential for Atara Biotherapeutics (ATRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

[url="]Atara Biotherapeutics, Inc.[/url] (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell plat

Atara Biotherapeutics (ATRA) plans to cut around 50% of its workforce, just a little over a week after the FDA declined to approve its immunotherapy Ebvallo. Read more here.

[url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biot

Atara Biotherapeutics (ATRA) stock slips as company faces an FDA clinical hold after rejection of lead candidate Ebvallo. Read more here.

[url="]Atara Biotherapeutics, Inc.[/url] (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell plat

Atara Biotherapeutics has just announced a CRL by FDA for EBVALLO. Click here to read more about ATRA stock and why it is rated as a Buy.

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling over 150 points on Thursday. The Dow traded down 0.27% to 43,106.65 while...

U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 0.1% on Thursday. The Dow traded up 0.08% to 43,256.69 while the NASDA...

U.S. stocks traded slightly lower this morning, with the Dow Jones index falling around 0.2% on Thursday. Following the market opening Thursday, the Dow traded...

Atara stock plummets on FDA setback for EBV drug

[url="]Atara Biotherapeutics, Inc.[/url] (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell plat

Here, we discuss some reasons why buying ATRA stock now may turn out to be a prudent move.

Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The FDA decision on Datopotamab Deruxtecan, proposed for the treatment of patients with previously treated metastatic HR-positive, HER2-negative breast cancer, is due on January 29, 2025.

**media[483102]**

MIAMI, Dec. 04, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 77th Emerging Growth Co

**media[481925]**

MIAMI, Dec. 03, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 77th Emerging Growth Co